Ischemic StrokeLeAAPSNCT05478304
Left Atrial Appendage Exclusion for Prophylactic Stroke Reduction Trial
A study testing AtriClip LAA Exclusion System in people with Ischemic Stroke and Systemic Embolism, run by AtriCure, Inc. at 138 sites in 10 countries.
Trial summary
This trial is a prospective, randomized, multicenter, multinational, blinded, superiority trial. The objective of this trial is to evaluate the effectiveness of left atrial appendage exclusion (LAAE) for the prevention of ischemic stroke or systemic arterial embolism in subjects undergoing cardiac surgery who have… Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Ischemic Stroke, Systemic Embolism
- What is being tested?
- AtriClip LAA Exclusion System
- Type of treatment
- Medical device
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 6,573 participants
- Where
- 138 sitesin 10 countries
- Study dates
- 25 Jan 2023to Apr 2032
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Subjects ≥ 18 years of age
- Documentation of any of the following clinical criteria:
- CHA2DS2-VASc ≥ 4 with age ≥ 65
- CHA2DS2-VASc ≥ 4 with significant left atrium enlargement or elevated NT-proBNP
- CHA2DS2-VASc = 3 with age ≥ 75
- CHA2DS2-VASc = 3 with significant left atrium enlargement or elevated NT-proBNP
- CHA2DS2-VASc score = 2 with age ≥ 65 and significant left atrium enlargement or elevated NT-proBNP
Who cannot join
- Clinically significant atrial fibrillation or atrial flutter:
- Anytime in the past and
- Documented by an electrocardiographic recording and
- Episode lasting 6 minutes or longer1*
- Prior procedure involving opening the pericardium or entering the pericardial space
- Prior LAA occlusion, exclusion, or removal (surgical or percutaneous)
Show all 18Show fewer
- Planned cardiac surgical procedure using non-sternotomy approaches
- o Partial sternotomies will be allowed.
- Patients whose planned procedure is a heart transplant or implantation of any ventricular assist devices
- Active endocarditis
- Active systemic infection at the time of cardiac surgery requiring antibiotics, including known SARS-CoV2 infections regardless of symptoms
- Known allergy to Nitinol or nickel sensitivity
- Known medical condition with expected survival of less than 1 year
- Other comorbidities that in the investigator's opinion make the subject unsuitable candidate to complete the protocol required visits.
- Current enrollment in an investigation or trial or an investigational devices or investigational drug that would interfere with this trial.
- Mental impairment or other psychiatric conditions which may not allow the patient to understand the nature, significance, and scope of the trial.
- Pregnancy
- Known severe symptomatic carotid disease
Trial locations and contacts
138 sites in 10 countries.
138 sites in 10 countries
United States102 sites
Lehigh Valley Health Network
Allentown, Pennsylvania, 18103
University of Michigan
Ann Arbor, Michigan, 48109
Emory University Hospital
Atlanta, Georgia, 30308
Piedmont Hospital
Atlanta, Georgia, 30309
HCA Florida JFK Hospital
Atlantis, Florida, 33462
UT Dell Medical School
Austin, Texas, 78705
Johns Hopkins Hospital
Baltimore, Maryland, 21287
Our Lady of the Lake Hospital
Baton Rouge, Louisiana, 70808
St. Luke's Regional Medical Center
Boise, Idaho, 83712
Massachusetts General Hospital
Boston, Massachusetts, 02114
Brigham and Women's Hospital
Boston, Massachusetts, 02115
Beth Israel Deaconess Medical Center
Boston, Massachusetts, 02215
University of Colorado
Boulder, Colorado, 80309
Ascension St. Vincent
Carmel, Indiana, 46290
Medical University of South Carolina (MUSC)
Charleston, South Carolina, 29425
Charleston Area Medical Center (CAMC)
Charleston, West Virginia, 25301
Atrium Health Carolinas Medical Center
Charlotte, North Carolina, 28203
Northwestern Memorial Hospital
Chicago, Illinois, 60611
TriHealth / Bethesda North Hospital
Cincinnati, Ohio, 45202
Christ Hospital / Lindner Research Center
Cincinnati, Ohio, 45219
University Hospitals of Cleveland
Cleveland, Ohio, 44106
Cleveland Clinic Foundation
Cleveland, Ohio, 44195
Ohio State Medical Center
Columbus, Ohio, 43210
Riverside Methodist
Columbus, Ohio, 43214
Mercy Medical Center
Coon Rapids, Minnesota, 55433
HCA Medical City Dallas
Dallas, Texas, 75243
University of Texas Southwestern
Dallas, Texas, 75390
Mercy Medical Center
Des Moines, Iowa, 50266
Duke University
Durham, North Carolina, 27705
Inova Fairfax Medical
Falls Church, Virginia, 22042
HealthPark Medical Center
Fort Myers, Florida, 33908
University of Florida Hospital
Gainesville, Florida, 32610
Corewell Health
Grand Rapids, Michigan, 49503
Hackensack University Medical Center
Hackensack, New Jersey, 07601
UPMC Pinnacle
Harrisburg, Pennsylvania, 17050
Hartford Hospital
Hartford, Connecticut, 06102
Memorial Regional Hospital
Hollywood, Florida, 33021
Houston Methodist Hospital
Houston, Texas, 77030
Heart Center Research / Huntsville Hospital
Huntsville, Alabama, 35801
Portneuf Medical Center
Idaho Falls, Idaho, 83404
Franciscan
Indianapolis, Indiana, 46237
University of Iowa Hospitals and Clinics
Iowa City, Iowa, 52245
Jackson Madison County General
Jackson, Tennessee, 38301
Baptist Health Jacksonville
Jacksonville, Florida, 32207
St. Bernard's Heart & Vascular
Jonesboro, Arkansas, 72401
St. Luke's Hospital
Kansas City, Kansas, 64111
Kansas University Medical Center
Kansas City, Kansas, 66160
Midwest Heart and Vascular (HCA)
Kansas City, Missouri, 64132
Lancaster General Hospital
Lancaster, Pennsylvania, 17602
Baptist Health
Lexington, Kentucky, 40503
University of Kentucky
Lexington, Kentucky, 40536
CHI St. Vincent
Little Rock, Arkansas, 72205
Arkansas Heart Hospital
Little Rock, Arkansas, 72211
Memorial Care Long Beach Medical Center
Long Beach, California, 90806
Keck Medical Center of USC
Los Angeles, California, 90033
Norton Healthcare
Louisville, Kentucky, 40202
University of Louisville Health / Jewish Hospital
Louisville, Kentucky, 40202
Novant Presbyterian Hospital
Louisville, Kentucky, 40205
North Shore University Hospital (Northwell)
Manhasset, New York, 11030
Wellstar - Kennestone
Marietta, Georgia, 30060
Loyola University Medical Center
Maywood, Illinois, 60153
Baptist Health South Florida
Miami, Florida, 33176
Abbott Northwestern / Minneapolis Heart
Minneapolis, Minnesota, 55407
West Virginia University
Morgantown, West Virginia, 26506
Centennial Medical Center (TriStar)
Nashville, Tennessee, 37203
Ascension St. Thomas West
Nashville, Tennessee, 37205
Christiana Care Health Services
Newark, Delaware, 19718
Hoag Memorial Hospital Presbyterian
Newport Beach, California, 92663
Sentara Hospitals & Sentara Medical Group
Norfolk, Virginia, 23507
Nebraska Methodist
Omaha, Nebraska, 68114
The Nebraska Medical Center
Omaha, Nebraska, 68198
Orlando Regional Medical Center
Orlando, Florida, 32806
Allegheny General Hospital
Pittsburgh, Pennsylvania, 15212
UPMC Health System
Pittsburgh, Pennsylvania, 15232
Baylor Heart Hospital - Plano
Plano, Texas, 75093
WakeMed Health & Hospitals
Raleigh, North Carolina, 27610
Mayo Clinic
Rochester, Minnesota, 55905
St. Francis Hospital
Roslyn, New York, 11576
Corewell Health East
Royal Oak, Michigan, 48073
Sutter Sacramento Hospital
Sacramento, California, 95816
University of Utah
Salt Lake City, Utah, 84132
Sarasota Memorial Hospital
Sarasota, Florida, 34239
HonorHealth Shea Scottsdale Healthcare
Scottsdale, Arizona, 85258
Swedish Heart and Vascular Research
Seattle, Washington, 98122
Sanford USD Medical Center
Sioux Falls, South Dakota, 57105
Memorial Hospital (SIU Medicine)
Springfield, Illinois, 62702
St. Lukes Hospital
St Louis, Missouri, 63017
Washington University
St Louis, Missouri, 63110
Mercy Hospital St. Louis
St Louis, Missouri, 63141
Stanford University
Stanford, California, 94305
St. Joseph Hospital
Syracuse, New York, 13203
Tampa General Hospital
Tampa, Florida, 33606
Baycare Health System
Tampa, Florida, 33607
The Toledo Hospital (Promedica)
Toledo, Ohio, 43606
Munson Medical Center
Traverse City, Michigan, 49684
North Mississippi Medical Center
Tupelo, Mississippi, 38801
Trinity Mother Frances (CHRISTUS)
Tyler, Texas, 75702
Medstar Washington Hospital Center
Washington D.C., District of Columbia, 20010
Aspirus Hospital
Wausau, Wisconsin, 54401
Wake Forest Baptist
Winston-Salem, North Carolina, 27157
Lankenau Hospital
Wynnewood, Pennsylvania, 19096
Trinity Health (formerly St. Joseph Mercy)
Ypsilanti, Michigan, 48197
Canada14 sites
Foothills Medical Centre
Calgary, Alberta, T2N 2T9
University of Alberta Hospital
Edmonton, Alberta, T6G 2B7
Queen Elizabeth II - Nova Scotia Health
Halifax, Nova Scotia, B3H 3A7
Hamilton General Hospital
Hamilton, Ontario, L8L 2X2
Kingston General Hospital
Kingston, Ontario, K7L 2V7
London Health Sciences Centre
London, Ontario, N6A 5A5
Centre Hospitalier de l'Université de Montréal (CHUM)
Montreal, Quebec, H1T 1C8
Montreal Heart Institute
Montreal, Quebec, H1T 1C8
Royal Columbian Hospital
New Westminster, British Columbia, V3L 3W7
Ottawa Heart Institute
Ottawa, Ontario, K1Y 4W7
IUCPQ Hosptial Laval
Québec, G1V 4G5
New Brunswick Heart Centre
Saint John, New Brunswick, E2L 4L2
St Michael's Hospital
Toronto, Ontario, M5B 1W8
Toronto General Hospital
Toronto, Ontario, M5G 2C4
Germany6 sites
Rhön-Klinikum Campus Bad Neustadt
Bad Neustadt an der Saale, Bavaria, 97616
Bad Rothefelde Schüchtermann-Klinik
Bad Rothenfelde, Lower Saxony, 49 49214
Deutsches Herzzentrum der Charité
Berlin, Brandenburg, 13353
University Heart Venter Freiburg Bad Krozingen
Freiburg im Breisgau, Baden-Wurttemberg, 79106
University Heart and Vascular Center Hamburg
Hamburg, 20246
Albertinen Krankenhaus
Hamburg, 22457
United Kingdom5 sites
Royal Papworth Hospital
Cambridge, CB2 0AY
St. Bartholomew's Hospital
London, Greater London, EC1A 7BE
The James Cook University Hospital
Middlesbrough, North Yorkshire, TS4 3BW
Northern General Hospital
Sheffield, Great Britain, S5 7AU
The Royal Wolverhampton NHS Trust
Wolverhampton, West Midlands, WV10 0QP
Australia3 sites
Victorian Heart Hospital and Monash University
Clayton, Victoria, 3168
St. Vincent's Hospital Melbourne
Fitzroy, Victoria, 3065
Gold Coast University Hospital
Southport, Queensland, 4215
Austria2 sites
Medical University Hospital Graz
Graz, Styria, 8036
Medical University Vienna
Vienna, 1090
Belgium2 sites
UZ Brussels
Jette, Brussels Capital, 1090
University Hospitals UZ Leuven
Leuven, Brabant, 3000
Spain2 sites
Hospital Clinic Barcelona
Barcelona, 08036
Hospital Clinico San Carlos
Madrid, 28040
New Zealand1 site
Waikato Hospital-Hamilton
Hamilton, Waikato Region, 3240
About this study
This trial is a prospective, randomized, multicenter, multinational, blinded, superiority trial. The objective of this trial is to evaluate the effectiveness of left atrial appendage exclusion (LAAE) for the prevention of ischemic stroke or systemic arterial embolism in subjects undergoing cardiac surgery who have risk factors for atrial fibrillation and ischemic stroke.
- Conditions
- Ischemic Stroke, Systemic Embolism
- Being tested
- AtriClip LAA Exclusion System
- Medical subject headings
- Ischemic Stroke
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
AtriClip LAA Exclusion SystemDevice
LAAE using the AtriClip concomitant to and at the time of planned cardiac surgery
| Study group | Role | What they receive |
|---|---|---|
| Treatment | Experimental | LAAE using the AtriClip concomitant to and at the time of planned cardiac surgery Receives: Device: AtriClip LAA Exclusion System |
| Control | No intervention | No LAAE concomitant to and at the time of planned cardiac surgery |
What is being measured
The primary outcome is the main question the study is designed to answer.
Primary Effectiveness Endpoint
Time to the first occurrence of ischemic stroke or systemic arterial embolism as adjudicated by the Clinical Events Committee (CEC), or any procedure wherein the LAA was excluded, occluded, or amputated following the index procedure.
Measured: Common termination point (median follow-up for 5 years)
Primary Safety Endpoint
Occurrence of at least one of the following events assessed through 30 days post index procedure:
- Pericardial effusion requiring percutaneous or surgical treatment
- Major bleeding attributable to index surgical procedure
- Deep sternal wound infection
- Myocardial infarction
Measured: 30 days post index procedure
Secondary outcomes (1)
Powered Secondary Effectiveness endpoint
Time to the first occurrence of ischemic stroke or systemic arterial embolism
Measured: Common termination point (median follow-up for 5 years)
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted28 Jul 2022
- Study start25 Jan 2023
- Primary completionDec 2031 (estimated)
- Study completionApr 2032 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for Ischemic StrokeStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Triple blind
- Who is masked
- Participant, Care provider, Outcomes assessor
- Enrolment
- 6,573 participants (actual)
Sponsor and investigators
- Lead sponsor
- AtriCure, Inc.
- Sponsor type
- Industry (pharma, biotech, devices)
- Collaborators
- Population Health Research Institute
- Responsible party
- Sponsor
- Investigators
- Richard Whitlock, MD, Study chair, McMaster University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT05478304
- Sponsor's protocol ID
- CP-2021-05
- Acronym
- LeAAPS
- Status last verified
- Mar 2026
- First submitted
- 15 Jul 2022
- Last updated
- 24 Mar 2026
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- Yes
- Individual data sharing
- No
Publications
Whitlock RP, McCarthy PM, Gerdisch MW, Ramlawi B, Alexander JH, Sultan I, Rose DZ, Healey JS, Sharma YA, Belley-Cote EP, Connolly SJ. The left atrial appendage exclusion for prophylactic stroke reduction (LEAAPS) trial: Rationale and design. Am Heart J. 2025 Jun;284:94-102. doi: 10.1016/j.ahj.2024.10.006. Epub 2024 Oct 11.
PubMed 39395566
Study at a glance
From the registry record, last updated by the sponsor on 24 Mar 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Left Atrial Appendage Exclusion for Prophylactic Stroke Reduction Trial
- ClinicalTrials.gov ID
- NCT05478304
- Acronym / sponsor ID
- LeAAPS / CP-2021-05
- Conditions
- Ischemic Stroke, Systemic Embolism
- Study type
- Interventional
- Recruitment status
- Active, not recruiting
- Enrolment
- 6,573 participants (actual)
- Lead sponsor
- AtriCure, Inc.Industry (pharma, biotech, devices)
- Collaborators
- Population Health Research Institute
- Study start
- 25 Jan 2023 (actual)
- Primary completion
- Dec 2031 (estimated)
- Study completion
- Apr 2032 (estimated)
- First posted
- 28 Jul 2022 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This trial is a prospective, randomized, multicenter, multinational, blinded, superiority trial. The objective of this trial is to evaluate the effectiveness of left atrial appendage exclusion (LAAE) for the prevention of ischemic stroke or systemic arterial embolism in subjects undergoing cardiac surgery who have risk factors for atrial fibrillation and ischemic stroke.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Triple blind (participant, care provider, outcomes assessor)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Treatment | Experimental | Device: AtriClip LAA Exclusion SystemLAAE using the AtriClip concomitant to and at the time of planned cardiac surgery |
| Control | No intervention | –No LAAE concomitant to and at the time of planned cardiac surgery |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (7 listed)
- Subjects ≥ 18 years of age
- Documentation of any of the following clinical criteria:
Key exclusion criteria (18 listed)
- Clinically significant atrial fibrillation or atrial flutter:
- Prior procedure involving opening the pericardium or entering the pericardial space
- Prior LAA occlusion, exclusion, or removal (surgical or percutaneous)
- Planned cardiac surgical procedure using non-sternotomy approaches
- o Partial sternotomies will be allowed.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| AtriClip LAA Exclusion SystemLAAE using the AtriClip concomitant to and at the time of planned cardiac surgery | Device | Treatment |
Primary outcome
Primary Effectiveness Endpoint
Time frame: Common termination point (median follow-up for 5 years)
Time to the first occurrence of ischemic stroke or systemic arterial embolism as adjudicated by the Clinical Events Committee (CEC), or any procedure wherein the LAA was excluded, occluded, or amputated following the index procedure.
Primary Safety Endpoint
Time frame: 30 days post index procedure
Occurrence of at least one of the following events assessed through 30 days post index procedure: * Pericardial effusion requiring percutaneous or surgical treatment * Major bleeding attributable to index surgical procedure * Deep sternal wound infection * Myocardial infarction
1 secondary outcome
Powered Secondary Effectiveness endpoint
Time frame: Common termination point (median follow-up for 5 years)
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 24 Mar 2026.
- Derived from this study: PubMed 39395566Whitlock RP, McCarthy PM, Gerdisch MW, Ramlawi B, Alexander JH, Sultan I, Rose DZ, Healey JS, Sharma YA, Belley-Cote EP, Connolly SJ. The left atrial appendage exclusion for prophylactic stroke reduction (LEAAPS) trial: Rationale and design. Am Heart J. 2025 Jun;284:94-102. doi: 10.1016/j.ahj.2024.10.006. Epub 2024 Oct 11.
- Individual participant dataSharing planned: No
Related trials for Ischemic Stroke
Recruiting
Delay AvoIding Primary Evaluation for ThRombectomy of Acute StrokE Patients With Large Vessel OCclusion in the Angiography SuiTe
Stroke, Acute
Not yet recruiting
EEG Feedback-Based Vagus Nerve Stimulation for Post-Stroke Dysphagia
Ischemic Stroke, Post-stroke Dysphagia
RecruitingObservational study
Development and Validation of Risk Prediction Models for Stroke and Cognitive Impairment in Moyamoya Disease and Moyamoya Syndrome
Moyamoya Disease, Moyamoya Syndrome
Recruiting
Impact of Atrial Fibrosis Surface Area on the Occurrence of Atrial Fibrillation in Patients With Ischemic Stroke of Undetermined Origin: a Prospective Cardiac MRI Pilot Study.
Stroke, Implantation of an Implantable Cardiac Monitor
Recruiting
Feasibility of the BrainGate2 Neural Interface System in Persons With Tetraplegia (BG-Tablet-01)
Brainstem Stroke, ALS
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Richard Whitlock, MD study chair
McMaster University
138 sites in 10 countries: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing AtriClip LAA Exclusion System in people with Ischemic Stroke and Systemic Embolism, run by AtriCure, Inc. at 138 sites in 10 countries.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 7 inclusion and 18 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: under way, not looking for participants, as of the sponsor's last update on 24 Mar 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 138 sites in United States, Canada, Germany, United Kingdom, Australia and 5 more countries. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Primary Effectiveness Endpoint (time frame: Common termination point (median follow-up for 5 years)). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT05478304, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 24 Mar 2026.